ClinicalTrials.gg
RecruitingNCT06552169RETIREUpdated Nov 19, 2026

REgulatory T Cell Therapy to Achieve Immunosuppression REduction

A Phase 2 interventional study of Arm 1: SOC (mTOR + CNI) and Arm 2A: TRACT/MONO mTOR in Kidney Transplantation, sponsored by Singulera Therapeutics Inc.. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Singulera Therapeutics Inc. · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 19, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Kidney Failure, Chronic with a site in Taiwan — 11 open to participants now, 13 under way, 2 of them phase 3. Kidney Failure, Chronic · Taiwan.

Planned enrollment
45th of 52
34 · median 80
Started
2025
with 3 others
Phase 2
4 of 70
2 open now
Primary completion
2027-12
later than 8 of 12 live
Registered
61st of 70
by date

Among the 70 studies in Kidney Failure, Chronic with a site in Taiwan, this one is the 45th largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 8 of the 12 other live ones, and was the 61st registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

11 of the 70 studies in Kidney Failure, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Kidney Failure, Chronic with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients.

Enrolled subjects will be randomized to one of 2 study arms:

Arm 1 subjects will receive standard of care immunosuppression

Arm 2 subjects will receive initial standard of care (SOC) immunosuppression and a single infusion of TRK-001. Three months after the transplant, Arm 2 subjects may be able to begin reducing their immunosuppression medication to a 1-drug regimen.

The primary outcome measures of trial are to evaluate several components indicating immunologic problems with the transplanted organ at 1-year post-transplant and to evaluate the ability for the study subjects given TRK-001 to wean to a 1-drug immunosuppression regimen.

All enrolled subjects will be followed for 5 years post-transplant.

Read the detailed description

This is a prospective, multi-national, multi-center, open-label, randomized Phase 2 trial to determine the safety and efficacy of administering autologous expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients.

All subjects will be followed for 5 years post-transplant, comprising of a 2-year post-transplant follow-up period and a 3-year surveillance period.

Subjects with end-stage renal disease undergoing a living donor kidney transplant will be enrolled into the trial as follows:

Arm 1 SOC: Standard of care immunosuppression (N=14)

Arm 2 TRACT/MONO: TRK-001 and initial SOC immunosuppression weaned to monotherapy (N=20)

At Month 3 post-transplant, Arm 2 subjects will be further randomized prior to weaning to either mTOR or CNI monotherapy as follows:

Arm 2A: TRACT/MONO mTOR (N=10) or Arm 2B: TRACT/MONO CNI (N=10)

03

Conditions studied

  • Kidney Transplantation

Keywords

  • Regulatory T cells
  • Treg adoptive cell transfer (TRACT)
  • Kidney Transplantation
  • Graft Rejection
  • Autologous cell therapy
  • End stage renal disease
  • Prevention of organ transplant rejection
  • Tregs
  • Reduced immunosuppression
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All inclusion criteria must be met prior to randomization.

  1. Males or females aged 18-65 years as of the date of who will undergo a single organ, living donor kidney transplant.
  2. Donor aged 18-65 years as of the date of organ donation. A certain degree of HLA matching between the donor and the recipient is not required.
  3. Blood type compatibility between recipient and donor must be established as follows.

    Recipient A to Donor A or O; Recipient B to Donor B or O; Recipient AB to Donor A, B, AB, or O; Recipient O to Donor O.

  4. No prior organ transplant of any kind.
  5. Women of must agree to use a medically acceptable method of throughout the trial. A list of the medically acceptable methods of contraception are listed in the informed consent document.
  6. Male patients must agree to use birth control following the initiation of standard-of-care and for a minimum of 6 months following kidney transplant.
  7. Subjects (recipients) must be able to understand the consent form and give written informed consent prior to any trial procedure.
  8. If donor informed consent is required by IRB/IEC, donor must be able to understand the consent form and give written informed consent prior to any trial procedure. Note: Donor informed consent is required for donors participating in the research assay collections.

Exclusion Criteria Based on SOC Pre-Transplant Evaluation

The following exclusion criteria must be determined prior to randomization per SOC pre-transplant evaluation.

  1. Known sensitivity or to thymoglobulin, everolimus, sirolimus, or tacrolimus or other immunosuppression medication prescribed.
  2. Subjects with a positive crossmatch by virtual cross matching or complement-dependent cytotoxicity (CDC) cross matching or flow cytometry cross matching (FCXM).
  3. Subjects with PRA >80% per SOC pre-transplant assessment. PRA must be repeated prior to transplant if patient receives a blood product transfusion after the initial assessment.
  4. Subjects with current or historic donor specific antibodies.
  5. (BMI) of \< 16 kg/m2 or > 38 kg/m2 per SOC pre-transplant evaluation.
  6. Subjects who are pregnant or nursing mothers.
  7. Subjects whose is severely limited by diseases other than renal disease, per judgement of an investigator.
  8. Ongoing active drug or alcohol substance abuse, per judgement of an investigator.
  9. Major ongoing psychiatric illness or recent history of noncompliance with current medical therapy, per judgement of an investigator.
  10. Significant cardiovascular disease (e.g.):

    • Significant non-correctable coronary artery disease, per judgement of an investigator
    • below 30% per SOC echocardiogram if an echocardiogram is performed for an individual subject as part of their pre-transplant evaluation
    • History of recent (\< 12 months) myocardial infarction at time of informed consent
    • History of recent (within 3 months) vascular intervention(s) for coronary artery disease at the time of informed consent
    • Documented arrhythmias that require a pacemaker or medical therapy for control.
  11. Subjects who require use of chronic anticoagulation medications. Use of anti- medications will be allowed in absence of a documented arrhythmia.
  12. within 3 years, excluding non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma.
  13. Serologic evidence of active infection with , or per SOC pre-transplant evaluation. Historical data within three months of transplant are acceptable.
  14. Subjects with a total white blood cell count \< 4,000/mm3; platelet count \< 50,000/mm3; triglyceride > 400 mg/dL; total cholesterol > 300 mg/dL, \<8.4 seconds or >15.7 seconds, activated partial thromboplastin time \<21.6 or > 42.3 seconds, fibrinogen \<177 mg/dL or >598 mg/dL, and INR \<0.64 or >1.4.
  15. Subjects with underlying renal disease etiologies with high risk of disease recurrence such as primary focal segmental glomerulosclerosis and others per investigator discretion.
  16. Subjects requiring the use of chronic immunosuppressive medication to control an underlying renal disease, or a disease with extrarenal manifestations (i.e., inflammatory bowel disease). Subjects requiring chronic or intermittent use of inhaled for respiratory conditions will be allowed.
  17. Diabetic subjects with an of >8%.

    The following exclusion criteria must be determined prior to transplant per SOC pre-transplant evaluation.

  18. Subjects with an active infection considered by an investigator that has not resolved prior to transplant.

Exclusion criteria

Exclusion Criteria Prior to Leukapheresis (Arm 2)

  1. Subjects with an active infection considered by an investigator that has not resolved prior to leukapheresis.
  2. Subjects with PRA >80%, if repeated after SOC pre-transplant assessment. (PRA must be repeated prior to leukapheresis if patient receives a blood product transfusion after the initial assessment).
  3. Subjects who are pregnant or nursing.
  4. Subjects who received an drug within 30 days prior to leukapheresis.
  5. Subjects who received anti-T cell therapy within 30 days prior to leukapheresis.
  6. Subjects who do not meet pre-leukapheresis clearance parameters per institutional practices or per investigator discretion.

Exclusion Criteria Prior to TRACT Cellular Product Infusion (Arm 2)

  1. Subjects with an active infection considered clinically significant by the investigator that has not resolved prior to planned Treg infusion.
  2. Subjects with a new, clinically significant medical condition that, per investigator opinion, would impact the ability to safely administer TRK-001.
  3. Subjects who experience a rejection episode of the kidney graft prior to the planned Treg infusion.
  4. Subjects who are pregnant or nursing. Women who are of must have a negative urine or serum pregnancy test before infusion of TRK-001.
  5. Subjects who received an investigational drug within 30 days prior to infusion.
  6. Subjects who received anti-T cell therapy within 30 days prior to infusion.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Active comparator
    Arm 1: Standard of Care (SOC)

    Arm 1: SOC-Subjects randomized to Arm 1 will be followed on the prescribed 2-drug SOC immunosuppression throughout the trial. The study allowed SOC regimen is tacrolimus + sirolimus or everolimus.

    Drug: Arm 1: SOC (mTOR + CNI)

  • Experimental
    Arm 2A: TRACT/MONO mTOR

    Arm 2: TRACT/MONO- At the beginning of the trial, subjects randomized to Arm 2 will be maintained on the prescribed 2-drug SOC immunosuppression and have a single infusion of expanded Tregs (TRK-001) at Day +53 to +67 following living donor kidney transplantation. At Month 3 post-transplant, Arm 2 TRACT/MONO subjects will be further randomized to either Arm 2A: TRACT/MONO mTOR or Arm 2B: TRACT/MONO CNI. Subjects randomized to Arm 2A: TRACT/MONO mTOR who have a normal biopsy and no de novo donor specific antibodies at Month 3 will begin weaning of tacrolimus and will remain on a 1-drug regimen with either everolimus or sirolimus until the end of the trial.

    Biological: Arm 2A: TRACT/MONO mTOR

  • Experimental
    Arm 2B: TRACT/MONO CNI

    Arm 2: TRACT/MONO- At the beginning of the trial, subjects randomized to Arm 2 will be maintained on the prescribed 2-drug SOC immunosuppression and have a single infusion of expanded Tregs (TRK-001) at Day +53 to +67 following living donor kidney transplantation. At Month 3 post-transplant, Arm 2 TRACT/MONO subjects will be further randomized to either Arm 2A: TRACT/MONO mTOR or Arm 2B: TRACT/MONO CNI. Subjects randomized to Arm 2B: TRACT/MONO CNI who have a normal biopsy and no de novo donor specific antibodies at Month 3 will begin weaning of the mTOR medication and will remain on a 1-drug regimen with low dose tacrolimus until the end of the trial.

    Biological: Arm 2B: TRACT/MONO CNI

Interventions

  • DrugArm 1: SOC (mTOR + CNI)

    Subjects randomized to Arm 1 will remain on standard dual-immunosuppression therapy (CNI and mTOR) throughout the trial.

    Also known as: sirolimus or everolimus + tacrolimus

  • BiologicalArm 2A: TRACT/MONO mTOR

    All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either: * Arm 2A: mTOR monotherapy or * Arm 2B: CNI monotherapy. These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant. Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.

    Also known as: TRK-001 + sirolimus or everolimus

  • BiologicalArm 2B: TRACT/MONO CNI

    All subjects will be prescribed standard of care (SOC) immunosuppressive agents. Subjects randomized to Arm 2 will be maintained on the prescribed SOC immunosuppression (tacrolimus + sirolimus or everolimus) and have a single intravenous infusion of autologous, expanded Tregs (TRK-001) at Day +53 to +67 post-transplant. At Month 3 post-transplant, Arm 2 subjects will be further randomized to receive either: * Arm 2A: mTOR monotherapy or * Arm 2B: CNI monotherapy. These subjects will transition to the assigned 1-drug immunosuppression regimen beginning at Month 3 post-transplant. Weaning must be completed by 12 months post-transplant. Subjects in Arm 2 will undergo leukapheresis to collect peripheral blood mononuclear cells required for the cellular product.

    Also known as: TRK-001 + tacrolimus

06

What researchers measure

Primary outcomes

  1. Development of de novo donor-specific antibodies

    A primary outcome measure for this study is to evaluate a composite endpoint of immunologic events against the allograft, where a failure is defined as patient-experienced immunologic events including the development of de novo donor-specific antibodies.

    Time frame: Month 12 Post-transplant

  2. Biopsy-proven acute rejection

    A primary outcome measure for this study is to evaluate a composite endpoint of immunologic events against the allograft, where a failure is defined as patient-experienced immunologic events including biopsy-proven acute rejection.

    Time frame: Month 12 Post-transplant

  3. Biopsy-proven subclinical rejection

    A primary outcome measure for this study is to evaluate a composite endpoint of immunologic events against the allograft, where a failure is defined as patient-experienced immunologic events including biopsy-proven subclinical rejection.

    Time frame: Month 12 Post-transplant

  4. Development of significant (2+) interstitial fibrosis/tubular atrophy

    A primary outcome measure for this study is to evaluate a composite endpoint of immunologic events against the allograft, where a failure is defined as patient-experienced immunologic events including the development of significant (2+) interstitial fibrosis/tubular atrophy.

    Time frame: Month 12 Post-transplant

  5. Successful taper to monotherapy (Arm 2)

    A primary outcome measure for this study is to evaluate the ability for Arm 2 subjects to successfully taper to monotherapy by one-year post-transplant.

    Time frame: Month 12 Post-transplant

Secondary outcomes

  1. Successful maintenance of monotherapy (Arm 2)

    A secondary outcome measure for this study is to evaluate the ability for Arm 2 subjects to successfully maintain monotherapy through two-years post-transplant.

    Time frame: Month 24 Post-transplant

  2. Development of de novo donor-specific antibodies

    A secondary outcome measure for this study is to evaluate overall and composite component-specific time to immunologic failure where a failure is defined as patient-experienced immunologic events including the development of de novo donor-specific antibodies.

    Time frame: To Month 60 Post-transplant

  3. Biopsy-proven acute rejection

    A secondary outcome measure for this study is to evaluate overall and composite component-specific time to immunologic failure where a failure is defined as patient-experienced immunologic events including biopsy-proven acute rejection.

    Time frame: To Month 60 Post-transplant

  4. Biopsy-proven subclinical rejection

    A secondary outcome measure for this study is to evaluate overall and composite component-specific time to immunologic failure where a failure is defined as patient-experienced immunologic events including biopsy-proven subclinical rejection.

    Time frame: To Month 60 Post-transplant

  5. Development of significant (2+) interstitial fibrosis/tubular atrophy

    A secondary outcome measure for this study is to evaluate overall and composite component-specific time to immunologic failure where a failure is defined as patient-experienced immunologic events including the development of significant (2+) interstitial fibrosis/tubular atrophy.

    Time frame: To Month 60 Post-transplant

  6. Graft loss

    A secondary outcome measure for the study is the incidence and timing of clinical outcomes, including graft loss. Graft loss is defined as 56 consecutive days of hemodialysis or re-transplantation.

    Time frame: To Month 60 Post-transplant

  7. Malignancy

    A secondary outcome measure for the study is the incidence and timing of clinical outcomes, including malignancy.

    Time frame: To Month 60 Post-transplant

  8. Infections

    A secondary outcome measure for the study is the incidence and timing of clinical outcomes, including infections (bacterial, viral, fungal).

    Time frame: To Month 60 Post-transplant

  9. Metabolic anomalies

    A secondary outcome measure for the study is the incidence and timing of clinical outcomes, including metabolic anomalies (e.g., diabetes mellitus, metabolic syndrome, hyperthyroidism, hypothyroidism).

    Time frame: To Month 60 Post-transplant

  10. Biopsy-proven acute rejection

    A secondary outcome measure for the study is to evaluate the incidence and timing of a composite endpoint of immunologic events against the allograft, where a failure is defined as patient-experienced immunologic event, including biopsy-proven acute rejection.

    Time frame: To Month 24 Post-transplant

  11. Graft loss

    A secondary outcome measure for the study is to evaluate the incidence and timing of a composite endpoint of immunologic events against the allograft, where a failure is defined as patient-experienced immunologic event, including graft loss. Graft loss is defined as 56 consecutive days of hemodialysis or re-transplantation.

    Time frame: To Month 24 Post-transplant

  12. Death (all cause)

    A secondary outcome measure for the study is to evaluate the incidence and timing of a composite endpoint of immunologic events against the allograft, where a failure is defined as patient- experienced immunologic event, including all cause death.

    Time frame: To Month 24 Post-transplant

  13. Quality of Life Measures by using KDQOL-SF

    The KDQOL-SF is an assessment tool designed for individuals with kidney disease to measure the impact of kidney disease and its treatment on a patient's quality of life.

    Time frame: To Month 60 Post-transplant

  14. Quality of Life Measures by using EQ-5D-5L

    The EQ-5D-5L is a standardized measurement tool to evaluate health status. The questionnaire has a descriptive section and a visual analog scale.

    Time frame: To Month 60 Post-transplant

  15. Safety- Adverse Events

    Incidence of adverse events

    Time frame: To Month 60 Post-transplant

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 26 industry-sponsored phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 30 months is above that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2024
First posted
Aug 13, 2024
StartActual
Jun 13, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2031
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
National Cheng Kung University Hospital is now Recruiting
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    National Cheng Kung University Hospital is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06552169
Lead sponsor
Singulera Therapeutics Inc.
Collaborators
Taiwan Bio Therapeutics Inc.
Responsible party
Sponsor
First posted
Aug 13, 2024
Start date
Jun 13, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2031 (estimated)
Last update
Nov 19, 2026

Study contacts

Susan B Murray
Contact
susan.murray@singulera-tx.com
+1-312-219-4670
Erwin Teng
Contact
erwin.teng@twbio-thera.com
+886-931-392700

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion